Michael Aaron Kelly

Insider Reports History

Location
New York, NY
Signature
/s/ Lindsey Rhodes, by Power of Attorney
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Michael Aaron Kelly:

Form 4 holding Director

NEOGENOMICS INC

Security class
Restricted Stock Unit
Shares / value
12,254
Estimated value
$192,878
Report date
01 Jun 2024
Price
$15.74
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

NEOGENOMICS INC

Security class
Restricted Stock Unit
Shares / value
23,077
Estimated value
$125,848
Report date
01 Jun 2025
Price
$10.27
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,254
Form 4 holding Director

NEOGENOMICS INC

Security class
Stock Option (Right to Buy)
Shares / value
16,107
Estimated value
$89,061
Report date
01 Jun 2025
Price
$10.27
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,672
Form 4 holding Director

NEOGENOMICS INC

Security class
Common Stock
Shares / value
5,000
Estimated value
$38,500
Report date
01 Jun 2025
Price
$7.70
Ownership
M Kelly & B Kelly TTEE Michael and Bonnie Kelly Revocable Trust DTD 05/02/2016
Form 4 holding Director

Aprea Therapeutics, Inc.

Security class
Common Stock
Shares / value
4,610
Estimated value
$16,969
Report date
30 Jun 2021
Price
$3.68
Ownership
Direct
Form 4 holding Director

Prime Medicine, Inc.

Security class
Stock Option (right to buy)
Shares / value
45,000
Estimated value
Report date
01 Aug 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

AMICUS THERAPEUTICS, INC.

Security class
Stock Options (right to buy)
Shares / value
42,467
Estimated value
Report date
06 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Aprea Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
22,750
Estimated value
Report date
30 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

HOOKIPA Pharma Inc.

Security class
Stock Option (Right to Buy)
Shares / value
20,000
Estimated value
Report date
30 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Michael Aaron Kelly

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .